BI 907828, BI 907828, Doxorubicin-Ebewe, 2 mg/ml, koncentrat do sporządzania roztworu do infuzji, BI 907828
1403-0008
Phase 3 small_molecule active
Quick answer
BI 907828, BI 907828, Doxorubicin-Ebewe, 2 mg/ml, koncentrat do sporządzania roztworu do infuzji, BI 907828 for Advanced dedifferentiated liposarcoma is a Phase 3 program (small_molecule) at Boehringer Ingelheim International GmbH with 1 ClinicalTrials.gov record(s).
Program details
- Company
- Boehringer Ingelheim International GmbH
- Indication
- Advanced dedifferentiated liposarcoma
- Phase
- Phase 3
- Modality
- small_molecule
- Status
- active